降压治疗与不良事件的相关性:系统评价与荟萃分析
该系统评价与荟萃分析纳入58项随机对照试验、280 638例成人患者,中位随访3年,比较降压治疗与安慰剂/无治疗、更多与更少降压药、更高与更低血压目标。结果显示降压治疗与跌倒无显著关联(RR 1.05,95%CI 0.89–1.24),但显著增加急性肾损伤(RR 1.18,95%CI 1.01–1.39)、高钾血症(RR 1.89,95%CI 1.56–2.30)、低血压(RR 1.97,95%CI 1.67–2.32)和晕厥(RR 1.28,95%CI 1.03–1.59)风险。降压治疗降低全因死亡、心血管死亡和卒中风险,但不降低心肌梗死风险。这些数据可用于医患共同决策,尤其对既往有不良事件或肾功能不全的高危患者。
要点
- 降压治疗与跌倒无显著关联(7项试验,汇总RR 1.05,95%CI 0.89–1.24),不应以担心跌倒为由常规停用降压药。
- 降压治疗显著增加高钾血症风险(26项试验,RR 1.89,95%CI 1.56–2.30),尤其涉及影响肾素-血管紧张素-醛固酮系统的药物。
- 降压治疗显著增加低血压风险(35项试验,RR 1.97,95%CI 1.67–2.32)和晕厥风险(16项试验,RR 1.28,95%CI 1.03–1.59)。
- 降压治疗增加急性肾损伤风险(15项试验,RR 1.18,95%CI 1.01–1.39),肾功能不全患者启动或维持降压治疗时需监测。
- 降压治疗降低全因死亡、心血管死亡和卒中风险,但不降低心肌梗死风险。
适用人群与场景
- 成人高血压患者,接受降压治疗(药物或血压目标管理)者。
- 纳入标准:比较降压药与安慰剂/无治疗、更多与更少降压药、或更高与更低血压目标的随机对照试验,且随访至少650患者年。
- 排除:早期小样本试验(因随访不足650患者年而被排除)。
- 场景:门诊/长期管理场景的降压治疗决策,非急诊/ICU特定场景。
诊断标准与关键阈值
- 原文未提及具体的血压诊断阈值或治疗启动/停止阈值。
- 纳入标准为随机对照试验,比较降压治疗与安慰剂/无治疗、更多与更少降压药、或更高与更低血压目标。
- 研究需至少650患者年随访。
处置流程与药物剂量
- 原文未提及具体的处置流程或药物剂量方案。
- 原文建议:这些数据可用于医患共同决策,讨论是否启动或继续降压治疗,尤其对因既往不良事件或肾功能不全而处于高风险的患者。
红旗征与不能漏的情况
- 高钾血症:降压治疗相关风险增加(RR 1.89,95%CI 1.56–2.30),尤其涉及影响肾素-血管紧张素-醛固酮系统的药物。
- 低血压:降压治疗相关风险增加(RR 1.97,95%CI 1.67–2.32)。
- 晕厥:降压治疗相关风险增加(RR 1.28,95%CI 1.03–1.59)。
- 急性肾损伤:降压治疗相关风险增加(RR 1.18,95%CI 1.01–1.39),尤其肾功能不全患者。
研究设计与关键结果
- 研究类型:系统评价与荟萃分析,纳入58项随机对照试验,280 638例参与者,中位随访3年(IQR 2–4)。
- 40项试验(69%)为低偏倚风险。
- 跌倒:7项试验报告,无证据显示与降压治疗相关(汇总RR 1.05,95%CI 0.89–1.24,τ²=0.009)。
- 急性肾损伤:15项试验,RR 1.18(95%CI 1.01–1.39,τ²=0.037);高钾血症:26项试验,RR 1.89(95%CI 1.56–2.30,τ²=0.122);低血压:35项试验,RR 1.97(95%CI 1.67–2.32,τ²=0.132);晕厥:16项试验,RR 1.28(95%CI 1.03–1.59,τ²=0.050)。
- 聚焦影响肾素-血管紧张素-醛固酮系统的药物时,急性肾损伤和高钾血症的异质性降低。
- 敏感性分析聚焦因不良事件退出试验者,结果稳健。
- 降压治疗与全因死亡、心血管死亡和卒中风险降低相关,但与心肌梗死风险降低无关。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析(随机对照试验)。
- 偏倚风险:40项试验(69%)为低偏倚风险,使用Cochrane偏倚风险评估工具。
- 局限性:原文未明确列出局限性;但异质性存在于部分不良事件分析中(如高钾血症τ²=0.122),且聚焦RAAS药物后异质性降低。
- 注册号:PROSPERO CRD42018116860。
对床旁实践的改变
- 不应以担心跌倒为由常规停用降压治疗(无证据支持跌倒风险增加)。
- 启动或继续降压治疗时,应监测急性肾损伤、高钾血症、低血压和晕厥,尤其对肾功能不全或既往有不良事件的高危患者。
- 使用影响肾素-血管紧张素-醛固酮系统的药物时,高钾血症和急性肾损伤风险需特别关注。
- 医患共同决策时应告知:降压治疗降低死亡和卒中风险,但增加上述不良事件风险。
- 不适用于:原文未提及急诊/ICU特定场景的适用性。
指南或共识出处
- 原文为系统评价与荟萃分析,未引用具体指南或共识名称。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To examine the association between antihypertensive treatment and specific adverse events.
DESIGN: Systematic review and meta-analysis.
ELIGIBILITY CRITERIA: Randomised controlled trials of adults receiving antihypertensives compared with placebo or no treatment, more antihypertensive drugs compared with fewer antihypertensive drugs, or higher blood pressure targets compared with lower targets. To avoid small early phase trials, studies were required to have at least 650 patient years of follow-up.
INFORMATION SOURCES: Searches were conducted in Embase, Medline, CENTRAL, and the Science Citation Index databases from inception until 14 April 2020.
MAIN OUTCOME MEASURES: The primary outcome was falls during trial follow-up. Secondary outcomes were acute kidney injury, fractures, gout, hyperkalaemia, hypokalaemia, hypotension, and syncope. Additional outcomes related to death and major cardiovascular events were extracted. Risk of bias was assessed using the Cochrane risk of bias tool, and random effects meta-analysis was used to pool rate ratios, odds ratios, and hazard ratios across studies, allowing for between study heterogeneity (τ2).
RESULTS: Of 15 023 articles screened for inclusion, 58 randomised controlled trials were identified, including 280 638 participants followed up for a median of 3 (interquartile range 2-4) years. Most of the trials (n=40, 69%) had a low risk of bias. Among seven trials reporting data for falls, no evidence was found of an association with antihypertensive treatment (summary risk ratio 1.05, 95% confidence interval 0.89 to 1.24, τ2=0.009). Antihypertensives were associated with an increased risk of acute kidney injury (1.18, 95% confidence interval 1.01 to 1.39, τ2=0.037, n=15), hyperkalaemia (1.89, 1.56 to 2.30, τ2=0.122, n=26), hypotension (1.97, 1.67 to 2.32, τ2=0.132, n=35), and syncope (1.28, 1.03 to 1.59, τ2=0.050, n=16). The heterogeneity between studies assessing acute kidney injury and hyperkalaemia events was reduced when focusing on drugs that affect the renin angiotensin-aldosterone system. Results were robust to sensitivity analyses focusing on adverse events leading to withdrawal from each trial. Antihypertensive treatment was associated with a reduced risk of all cause mortality, cardiovascular death, and stroke, but not of myocardial infarction.
CONCLUSIONS: This meta-analysis found no evidence to suggest that antihypertensive treatment is associated with falls but found evidence of an association with mild (hyperkalaemia, hypotension) and severe adverse events (acute kidney injury, syncope). These data could be used to inform shared decision making between doctors and patients about initiation and continuation of antihypertensive treatment, especially in patients at high risk of harm because of previous adverse events or poor renal function.
REGISTRATION: PROSPERO CRD42018116860.
参考来源
- Albasri A, Hattle M, Koshiaris C, et al. Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. BMJ. 2021. PMID: 33568342. doi:10.1136/bmj.n189
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。